Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18781208 | SYSTEMS AND METHODS FOR NATURAL LANGUAGE PROCESSING-BASED CLASSIFICATION OF ELECTRONIC MEDICAL RECORDS | July 2024 | January 2026 | Allow | 18 | 3 | 0 | Yes | No |
| 18658198 | SYSTEMS AND METHODS FOR MULTILABEL TEXT CLASSIFICATION FOR AUTOMATIC LABELING OF PATIENT SELF-REPORTS | May 2024 | March 2026 | Abandon | 22 | 1 | 0 | No | No |
| 18402288 | APPARATUSES AND METHODS FOR PAYMENT FOR CONSUMABLE CONTENT | January 2024 | September 2024 | Allow | 9 | 1 | 0 | No | No |
| 18556613 | DEEP NEURAL NETWORKS FOR PREDICTING POST-OPERATIVE OUTCOMES | October 2023 | November 2025 | Abandon | 25 | 1 | 0 | No | No |
| 18364470 | METHOD AND SYSTEM FOR DISCOVERING ADVERSE DRUG REACTION SIGNAL BASED ON CAUSAL DISCOVERY | August 2023 | January 2025 | Abandon | 18 | 2 | 0 | Yes | No |
| 18349700 | INDIVIDUALIZED MANAGEMENT SYSTEM FOR TREATING DISEASE, INCLUDING GI DISEASES, AND METHODS OF USE THEREOF | July 2023 | March 2026 | Abandon | 32 | 1 | 1 | No | No |
| 18313614 | Patient Registry System | May 2023 | September 2025 | Abandon | 28 | 2 | 0 | No | No |
| 18142508 | APPARATUS AND A METHOD FOR THE GENERATION OF A PLURALITY OF PERSONAL TARGETS | May 2023 | December 2024 | Allow | 19 | 4 | 0 | Yes | No |
| 18140383 | METHODS, SYSTEMS, AND COMPUTER-READABLE MEDIA FOR DECREASING PATIENT PROCESSING TIME IN A CLINICAL SETTING | April 2023 | May 2025 | Abandon | 25 | 1 | 0 | No | No |
| 18188974 | FALL RISK ANALYSIS USING BALANCE PROFILES | March 2023 | November 2025 | Abandon | 32 | 2 | 0 | No | No |
| 18075215 | INTELLIGENT ANALYTICS AND QUALITY ASSESSMENT FOR SURGICAL OPERATIONS AND PRACTICES | December 2022 | August 2025 | Abandon | 33 | 2 | 0 | No | No |
| 17959190 | SYSTEMS AND METHODS FOR CLAIM PROCESSING | October 2022 | January 2026 | Allow | 40 | 4 | 0 | No | No |
| 17842431 | SYSTEM AND METHOD FOR MONITORING SAFETY AND PRODUCTIVITY OF PHYSICAL TASKS | June 2022 | December 2025 | Abandon | 42 | 2 | 1 | No | Yes |
| 17564874 | METHOD FOR PREDICTING MEDICINAL EFFECTS OF COMPOUNDS USING DEEP LEARNING | December 2021 | November 2025 | Abandon | 47 | 3 | 0 | No | No |
| 17644224 | CONSUMER DEVICE PAYMENT TOKEN MANAGEMENT | December 2021 | December 2025 | Abandon | 48 | 4 | 0 | No | No |
| 17456588 | DISABILITY LEVEL AUTOMATIC JUDGMENT DEVICE AND A DISABILITY LEVEL AUTOMATIC JUDGMENT METHOD | November 2021 | November 2024 | Abandon | 36 | 1 | 0 | No | No |
| 17533993 | PATIENT PROVIDER MATCHING SYSTEM | November 2021 | November 2025 | Abandon | 48 | 2 | 0 | Yes | No |
| 17593203 | AN INTEGRATED HEALTH AND SECURITY MANAGEMENT SYSTEM | September 2021 | March 2025 | Abandon | 43 | 2 | 0 | No | No |
| 17436743 | INDIVIDUALIZED MEDICINE USING CAUSAL MODELS | September 2021 | April 2025 | Abandon | 43 | 2 | 0 | No | No |
| 17408895 | METHODS, SYSTEMS, AND COMPUTER PROGRAM PRODUCTS FOR DETERMINING THIRD PARTY LIABILITY FOR A CLAIM | August 2021 | March 2025 | Abandon | 42 | 4 | 0 | Yes | No |
| 17407211 | System and Method for Adaptive Auditory Wellness | August 2021 | July 2025 | Abandon | 47 | 4 | 0 | Yes | No |
| 17370306 | TRADING PLANNING APPARATUS AND TRADING PLANNING METHOD | July 2021 | December 2024 | Abandon | 42 | 3 | 0 | Yes | No |
| 17353621 | Automobile Monitoring Systems and Methods for Loss Reserving and Financial Reporting | June 2021 | November 2024 | Abandon | 40 | 3 | 0 | Yes | No |
| 17312827 | SYSTEM AND METHOD FOR DETECTION AND MONITORING OF OVER SEDATION TO PREVENT HARM TO PATIENTS | June 2021 | November 2024 | Abandon | 41 | 2 | 0 | No | No |
| 17342973 | CLASSIFYING AND ANSWERING MEDICAL INQUIRIES BASED ON MACHINE-GENERATED DATA RESOURCES AND MACHINE LEARNING MODELS | June 2021 | March 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17335893 | METHODS AND SYSTEMS FOR DECISION SUPPORT | June 2021 | December 2024 | Abandon | 43 | 2 | 0 | No | No |
| 17296688 | SYSTEM AND METHOD FOR MATCHING MEDICAL CONCEPTS IN RADIOLOGICAL REPORTS | May 2021 | October 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17210253 | Automated Clinical Documentation System and Method | March 2021 | August 2025 | Abandon | 53 | 1 | 1 | No | No |
| 17156318 | PREDICTION OF ADHESIONS BASED ON BIOMARKER MONITORING | January 2021 | December 2025 | Abandon | 59 | 4 | 0 | Yes | No |
| 17059162 | SYSTEM AND METHOD FOR EFFICIENTLY DELIVERING DATA TO TARGET USERS | November 2020 | August 2025 | Abandon | 56 | 6 | 0 | Yes | No |
| 16579221 | SYSTEM AND METHOD FOR UTILIZING PREPAID CARDS TO FACILITATE PURCHASES IN ASSOCIATION WITH A GAMING ESTABLISHMENT RETAIL ACCOUNT | September 2019 | March 2025 | Abandon | 60 | 6 | 0 | Yes | No |
| 16576519 | SYSTEMS AND METHODS FOR CARD REPLACEMENT | September 2019 | September 2024 | Allow | 60 | 8 | 0 | Yes | No |
| 16535984 | SECURE QR CODE TRANSACTIONS | August 2019 | May 2025 | Allow | 60 | 7 | 0 | Yes | Yes |
| 16420744 | Compliance Aware Crime Risk Avoidance System | May 2019 | November 2024 | Abandon | 60 | 5 | 0 | No | Yes |
| 14745688 | FAILURE MODELING BY INCORPORATION OF TERRESTRIAL CONDITIONS | June 2015 | September 2024 | Allow | 60 | 12 | 0 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MACCAGNO, PIERRE L.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 40.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner MACCAGNO, PIERRE L works in Art Unit 3687 and has examined 22 patent applications in our dataset. With an allowance rate of 13.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 48 months.
Examiner MACCAGNO, PIERRE L's allowance rate of 13.6% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MACCAGNO, PIERRE L receive 3.86 office actions before reaching final disposition. This places the examiner in the 97% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by MACCAGNO, PIERRE L is 48 months. This places the examiner in the 8% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +27.3% benefit to allowance rate for applications examined by MACCAGNO, PIERRE L. This interview benefit is in the 75% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 0.0% of applications are subsequently allowed. This success rate is in the 1% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 9.1% of cases where such amendments are filed. This entry rate is in the 9% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 99% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 75.0% of appeals filed. This is in the 66% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 40% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 43% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.